Cargando…

HTLV-1 uveitis

Human T cell lymphotropic virus type 1 (HTLV-1) is the first retrovirus described as a causative agent of human disease. Following adult T cell leukemia/lymphoma and HLTV-1-associated myelopathy/tropical spastic paraparesis, HTLV-1 uveitis (HU) has been established as a distinct clinical entity caus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kamoi, Koju, Mochizuki, Manabu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Research Foundation 2012
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403349/ https://www.ncbi.nlm.nih.gov/pubmed/22837757 http://dx.doi.org/10.3389/fmicb.2012.00270

Ejemplares similares

Mechanism of Secondary Glaucoma Development in HTLV-1 Uveitis
por: Zong, Yuan, et al.
Publicado: (2022)

HTLV-1 in Ophthalmology
por: Kamoi, Koju
Publicado: (2020)

Updates on HTLV-1 Uveitis
por: Kamoi, Koju, et al.
Publicado: (2022)

SUV39H1 interacts with HTLV-1 Tax and abrogates Tax transactivation of HTLV-1 LTR
por: Kamoi, Koju, et al.
Publicado: (2006)

Subtype Analysis of HTLV‐1 in Patients with HTLV‐1 Uveitis
por: Ono, Ayako, et al.
Publicado: (1994)

In vitro Evaluation of the Safety of Adalimumab for the Eye Under HTLV-1 Infection Status: A Preliminary Study
por: Kurozumi-Karube, Hisako, et al.
Publicado: (2020)

HTLV‐I Uveitis: A Distinct Clinical Entity Caused by HTLV‐I
por: Mochizuki, Manabu, et al.
Publicado: (1992)

Human Immunodeficiency Virus and Uveitis
por: Yang, Mingming, et al.
Publicado: (2023)

Dengue fever-associated necrotizing scleritis: A case report with long-term follow-up
por: Kamoi, Koju, et al.
Publicado: (2018)

Safety of intraocular anti-VEGF antibody treatment under in vitro HTLV-1 infection
por: Zong, Yuan, et al.
Publicado: (2023)

Cytomegalovirus Anterior Uveitis: Clinical Manifestations, Diagnosis, Treatment, and Immunological Mechanisms
por: Zhang, Jing, et al.
Publicado: (2023)

Long-term incidence of posterior capsular opacification in patients with non-infectious uveitis
por: Kitaguchi-Iwakiri, Yuki, et al.
Publicado: (2022)

Treatment of rheumatoid arthritis with biologics may exacerbate HTLV-1-associated conditions: A case report
por: Terada, Yukiko, et al.
Publicado: (2017)

Safety of Infliximab for the Eye Under Human T-Cell Leukemia Virus Type 1 Infectious Conditions in vitro
por: Uchida, Minami, et al.
Publicado: (2019)

Fine tuning of the temporal expression of HTLV-1 and HTLV-2
por: Cavallari, Ilaria, et al.
Publicado: (2013)

Novel perspectives on antisense transcription in HIV-1, HTLV-1, and HTLV-2
por: Lin, Edward, et al.
Publicado: (2022)

A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet’s syndrome
por: Horiguchi, Noe, et al.
Publicado: (2020)

Functional comparison of antisense proteins of HTLV-1 and HTLV-2 in viral pathogenesis
por: Barbeau, Benoit, et al.
Publicado: (2013)

Targeted delivery of autoantigen to dendritic cells prevents development of spontaneous uveitis
por: Klaska, Izabela P., et al.
Publicado: (2023)

The Exceptional Oncogenicity of HTLV-1
por: Tagaya, Yutaka, et al.
Publicado: (2017)

Prevalence and characteristics of HTLV-associated uveitis in patients from Bahia, an endemic area for HTLV − 1 in Brazil
por: Piai Ozores, Daniele, et al.
Publicado: (2023)

HTLV-1 HBZ Viral Protein: A Key Player in HTLV-1 Mediated Diseases
por: Baratella, Marco, et al.
Publicado: (2017)

Adult T-Cell Leukemia/Lymphoma-Related Ocular Manifestations: Analysis of the First Large-Scale Nationwide Survey
por: Kamoi, Koju, et al.
Publicado: (2019)

Real-world evidence of treatment for relapse of noninfectious uveitis in tertiary centers in Japan: A multicenter study
por: Takeuchi, Masaru, et al.
Publicado: (2019)

Editorial to the Research Topic “Comparative studies between HTLV-1 and HTLV-2 function and pathobiology”
por: Bertazzoni, Umberto
Publicado: (2015)

Forefront studies on HTLV-1 oncogenesis
por: Mahieux, Renaud, et al.
Publicado: (2013)

Editorial: Molecular Pathology of HTLV-1
por: Bertazzoni, Umberto, et al.
Publicado: (2018)

HTLV-1 Infection and Rheumatic Diseases
por: Umekita, Kunihiko, et al.
Publicado: (2020)

The Role of Chemokines in the Pathogenesis of HTLV-1
por: Zargari, Razieh, et al.
Publicado: (2020)

HBZ and its roles in HTLV-1 oncogenesis
por: Zhao, Tiejun, et al.
Publicado: (2012)

Pathways of cell-cell transmission of HTLV-1
por: Pique, Claudine, et al.
Publicado: (2012)

EZH1/2 dual inhibitors suppress HTLV-1-infected cell proliferation and hyperimmune response in HTLV-1-associated myelopathy
por: Koseki, Akihito, et al.
Publicado: (2023)

Cellular Factors Involved in HTLV-1 Entry and Pathogenicit
por: Hoshino, Hiroo
Publicado: (2012)

Epidemiological Aspects and World Distribution of HTLV-1 Infection
por: Gessain, Antoine, et al.
Publicado: (2012)

HTLV-1 Alters T Cells for Viral Persistence and Transmission
por: Tanaka, Azusa, et al.
Publicado: (2018)

Epidemiology of HTLV-1 Infection and ATL in Japan: An Update
por: Iwanaga, Masako
Publicado: (2020)

The need to accessorize: molecular roles of HTLV-1 p30 and HTLV-2 p28 accessory proteins in the viral life cycle
por: Anupam, Rajaneesh, et al.
Publicado: (2013)

HTLV-1: Regulating the Balance Between Proviral Latency and Reactivation
por: Kulkarni, Anurag, et al.
Publicado: (2018)

Role of HTLV-1 Tax and HBZ in the Pathogenesis of HAM/TSP
por: Enose-Akahata, Yoshimi, et al.
Publicado: (2017)

Mother-to-Child HTLV-1 Transmission: Unmet Research Needs
por: Rosadas, Carolina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2c1eel4tev5ure925pqttc6ase